Impact of SAVR and TAVR on Patient's Activity and Mobility

NCT ID: NCT03843320

Last Updated: 2020-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Total Enrollment

340 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-12-31

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an independent, investigator-initiated, prospective multicenter observational study with restricted grant provided by Edwards Lifesciences that aims to describe baseline (preoperative) physical function and to assess and compare 6-month postoperative changes in the physical function of patients undergoing aortic stenosis (AS) treatment with either transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) implanted with Edwards valve type ("SAPIEN 3" and "SAPIEN XT" for TAVR; "INSPIRIS RESILIA", "EDWARDS INTUITY" and "Carpentier-Edwards PERIMOUNT Magna-Ease" for SAVR).

Secondary objectives of this study are: to evaluate the validity of wearable devices in assessing physical function in such patients and subjects' compliance in wearing the device also after a very long follow-up time up to 12 months; to assess and compare 6-month postoperative changes in Health-Related Quality of Life (HRQoL), sleep quality, cognitive function of patients undergoing AS treatment with either TAVR or SAVR.

Smart watch activity tracker "Vívoactive® HR" devices by "Garmin©" will be used in the study. Devices will be distributed to the patients at time of baseline assessment, along with a Bluetooth-paired smartphone provided with a prepaid data-only SIM-card and study-customised interface. Patients will be asked to wear the device 24 hours a day, 7 days a week, from the baseline assessment to the last follow-up, 12 months after baseline.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Valve Stenosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

SAVR TAVR Physical function Aortic valve replacement Wearable devices Smart watch Activity tracker

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SAVR

Patients with aortic stenosis undergoing surgical aortic valve replacement using an approved medical device for this intended use.

Patients will be enrolled in this group only if the device is one of the following:

* INSPIRIS RESILIA;
* EDWARDS INTUITY;
* Carpentier-Edwards PERIMOUNT Magna-Ease.

INSPIRIS RESILIA

Intervention Type DEVICE

Surgical aortic valve replacement

EDWARDS INTUITY

Intervention Type DEVICE

Surgical aortic valve replacement

Carpentier-Edwards PERIMOUNT Magna-Ease

Intervention Type DEVICE

Surgical aortic valve replacement

TAVR

Patients with aortic stenosis undergoing transcatheter aortic valve replacement using an approved medical device for this intended use.

Patients will be enrolled in this group only if the device is one of the following:

* SAPIEN 3;
* SAPIEN XT.

SAPIEN 3

Intervention Type DEVICE

Transcatheter aortic valve replacement

SAPIEN XT

Intervention Type DEVICE

Transcatheter aortic valve replacement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SAPIEN 3

Transcatheter aortic valve replacement

Intervention Type DEVICE

SAPIEN XT

Transcatheter aortic valve replacement

Intervention Type DEVICE

INSPIRIS RESILIA

Surgical aortic valve replacement

Intervention Type DEVICE

EDWARDS INTUITY

Surgical aortic valve replacement

Intervention Type DEVICE

Carpentier-Edwards PERIMOUNT Magna-Ease

Surgical aortic valve replacement

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Severe native aortic valve stenosis symptomatic for heart failure or angina;
* Indication to isolated TAVR or SAVR given by heart team;
* TAVR through the trans-femoral approach;
* SAVR by any access;
* Implantation of an Edwards valve type (SAPIEN 3 and SAPIEN XT for TAVR; INSPIRIS RESILIA, EDWARDS INTUITY and Carpentier-Edwards PERIMOUNT Magna-Ease for SAVR);
* Signed informed consent.

Exclusion Criteria

* Use of walking aids;
* Dyskinesia or Parkinson's disease;
* Reduced survival expectancy due to severe co-morbidities (\<1 year);
Minimum Eligible Age

75 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Edwards Lifesciences

INDUSTRY

Sponsor Role collaborator

Ospedale San Bortolo di Vicenza

OTHER

Sponsor Role collaborator

Azienda Ospedaliera di Padova

OTHER

Sponsor Role collaborator

University of Padova

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Giuseppe Tarantini, MD

Role: PRINCIPAL_INVESTIGATOR

University of Padova

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Azienda Ospedaliera di Padova

Padua, PD, Italy

Site Status

Azienda ULSS n.8 Berica, Vicenza - Ospedale San Bortolo

Vicenza, VI, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

References

Explore related publications, articles, or registry entries linked to this study.

Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006 Sep 16;368(9540):1005-11. doi: 10.1016/S0140-6736(06)69208-8.

Reference Type BACKGROUND
PMID: 16980116 (View on PubMed)

van Geldorp MW, Heuvelman HJ, Kappetein AP, Busschbach JJ, Cohen DJ, Takkenberg JJ, Bogers AJ. Quality of life among patients with severe aortic stenosis. Neth Heart J. 2013 Jan;21(1):21-7. doi: 10.1007/s12471-012-0364-9.

Reference Type BACKGROUND
PMID: 23229811 (View on PubMed)

Stortecky S, Schmid V, Windecker S, Kadner A, Pilgrim T, Buellesfeld L, Khattab AA, Wenaweser P. Improvement of physical and mental health after transfemoral transcatheter aortic valve implantation. EuroIntervention. 2012 Aug;8(4):437-43. doi: 10.4244/EIJV8I4A69.

Reference Type BACKGROUND
PMID: 22917726 (View on PubMed)

Lorenzoni G, Azzolina D, Fraccaro C, Di Liberti A, D'Onofrio A, Cavalli C, Fabris T, D'Amico G, Cibin G, Nai Fovino L, Ocagli H, Gerosa G, Tarantini G, Gregori D. Using Wearable Devices to Monitor Physical Activity in Patients Undergoing Aortic Valve Replacement: Protocol for a Prospective Observational Study. JMIR Res Protoc. 2020 Nov 12;9(11):e20072. doi: 10.2196/20072.

Reference Type DERIVED
PMID: 33180023 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CAPABILITY

Identifier Type: -

Identifier Source: org_study_id